Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis.
10.4048/jbc.2017.20.4.347
- Author:
Jin Hyun PARK
1
;
Seock Ah IM
;
Ja Min BYUN
;
Ki Hwan KIM
;
Jin Soo KIM
;
In Sil CHOI
;
Hee Jun KIM
;
Kyung Hun LEE
;
Tae Yong KIM
;
Sae Won HAN
;
Do Youn OH
;
Tae You KIM
Author Information
1. Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Breast neoplasms;
Cyclophosphamide;
Fluorouracil;
Methotrexate;
Palliative care
- MeSH:
Breast Neoplasms*;
Breast*;
Cyclophosphamide*;
Diagnosis;
Disease-Free Survival;
Drug Therapy;
Fluorouracil*;
Humans;
Korea;
Methotrexate*;
Neutropenia;
Palliative Care*;
Retrospective Studies*;
Salvage Therapy
- From:Journal of Breast Cancer
2017;20(4):347-355
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study aimed to evaluate the efficacy and safety of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy beyond standard treatment for anthracycline- and taxane-pretreated metastatic breast cancer (MBC). METHODS: We consecutively enrolled 158 MBC patients who underwent CMF chemotherapy in a palliative setting at two academic hospitals in Korea between 2002 and 2016. RESULTS: The median age of the 158 enrolled patients was 51 years (range, 30–77 years). The enrolled patients were treated with a median of 5 lines of systemic treatment (range, 2–11) before CMF therapy, and the median time from diagnosis of MBC to CMF administration was 36.0 months (range, 7.1–146.7 months). The median number of cycles of CMF treatment was 3 (range, 1–19), and the relative dose intensity was 90.4%. The toxicity profile was mild, with an observed 3.1% of grade 2 and 5.0% of grade 3/4 neutropenia. Among 147 patients (93.0%) whose response to CMF was evaluated, the response rate was 10.9% (16/147), with complete response (CR) in one and partial response (PR) in 15. In addition, the disease control rate (calculated as CR+PR+stable disease) was 44.2% (65/147). The median progression-free survival and overall survival were 3.1 months (95% confidence interval [CI], 2.7–3.6) and 9.4 months (95% CI, 7.1–11.6), respectively. CONCLUSION: CMF therapy is effective and tolerable as salvage treatment for heavily pretreated MBC.
